Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl,
and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of
ZG0895.HCl.